nafamostat has been researched along with Urinary Tract Infections in 1 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Urinary Tract Infections: Inflammatory responses of the epithelium of the URINARY TRACT to microbial invasions. They are often bacterial infections with associated BACTERIURIA and PYURIA.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Machioka, K | 1 |
| Shigehara, K | 1 |
| Kadomoto, S | 1 |
| Iwamoto, H | 1 |
| Miyagi, T | 1 |
| Nakashima, T | 1 |
| Namiki, M | 1 |
1 other study available for nafamostat and Urinary Tract Infections
| Article | Year |
|---|---|
[Treatment with recombinant thrombomodulin on disseminated intravascular coagulation caused by urinary tract infections; a retrospective comparative study with control cases].
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzamidines; Disseminated Intravascular Coagulation; Femal | 2015 |